Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 9/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ICMT | O60725 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4035309 | 0.85 | ICMT (0.51) | ICMTMAPTTSHRKMT2AKDM4E | |
| SCHEMBL4354642 | 0.84 | ICMT (0.56) | ICMTMAPT | |
| SCHEMBL15971141 | 0.82 | NR4A2 (0.72) | NR4A2LMNAGAAMAPTL3MBTL1 | |
| SCHEMBL8738244 | 0.78 | POLB (0.47) | NR4A2LMNAGAAMAPTL3MBTL1 | |
| SCHEMBL3591554 | 0.73 | ALDH1A1 (0.44) | LMNAICMTMAPTTSHRKMT2A | |
| SCHEMBL24144558 | 0.73 | NR4A2 (0.58) | NR4A2ICMTGAA | |
| SCHEMBL7524478 | 0.73 | DYRK1A (0.46) | NR4A2LMNAGAAMAPTL3MBTL1 | |
| SCHEMBL8600636 | 0.71 | PDE4A (0.57) | MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL3596003 | 0.70 | ICMT (0.46) | ICMTKMT2A | |
| SCHEMBL31211717 | 0.70 | NR4A2 (0.66) | NR4A2LMNAGAATSHRBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | GLAXO GROUP LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | GLAXO GROUP LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | GLAXO GROUP LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| EP-2041126-A1 | INDOLE COMPOUNDS HAVING AFFINITY TO THE EP1 RECEPTOR | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008006794-A1 | INDOLE COMPOUNDS HAVING AFFINITY TO THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006794-A1 | INDOLE COMPOUNDS HAVING AFFINITY TO THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | PTGER1, PTGER2, PTGER3 | NR4A2 701/4885LMNA 3457/4885ICMT 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.